S

Sharp HealthCare | Sharp Center for Research

Research site

(Unclaimed)

Location

7930 Frost Street, Suite 300, San Diego, California, United States of America

Site insights

Top conditions

Top treatments

Gemcitabine

Docetaxel

Prednisone

Milvexian

MCLA-158

Sacituzumab

Enobosarm

Ompenaclid

Platinum

RCHOP

Parent organization

This site is a part of Sharp HealthCare

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

5 of 28 total trials

A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment

The purpose of the study is to evaluate the overall survival of participants treated with imetelstat compared to best available therapy with intermed...

Active, not recruiting

Myelofibrosis

Drug: Imetelstat

Drug: Best Available Therapy (BAT)

A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors

This is a Phase 1/2 open-label, multi-center, multi-national study with an initial dose escalation part to determine the recommended Phase II dose (R...

Enrolling

Esophageal Cancer

Gastric Cancer

Combination Product: MCLA-158 + FOLFOX

Combination Product: MCLA-158 + FOLFIRI

A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (LIBREXIA-ACS)

The purpose of this study is to evaluate that milvexian is superior to placebo, in addition to standard-of-care, in reducing the risk of major advers...

Active, not recruiting

Acute Coronary Syndrome

Drug: Milvexian

Other: Placebo

Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1)

A Phase 2 multi-center open-label basket trial of nab-sirolimus for adult and adolescent patients with malignant solid tumors harboring pathogenic in...

Active, not recruiting

Solid Tumor

Malignant Neoplasm

Drug: nab-sirolimus

Study of DF1001 in Patients with Advanced Solid Tumors

DF1001-001 is a study of a new molecule that targets natural killer (NK) cells and T-cell activation signals to specific receptors on cancer cells. T...

Enrolling

Solid Tumor, Adult

Drug: DF1001

Drug: Sacituzumab Govitecan-hziy